Abnormalities of keratinocyte maturation and differentiation in keratosis palmoplantaris striata. Immunohistochemical and ultrastructural study before and during etretinate therapy.
Keratoderma striatum (Brünauer-Fuhs type) with linear keratotic elevations on the palms and small islets (areata form) on the soles is a rare form of palmoplantar keratoderma (PPK). An immunohistochemical and ultrastructural study has been performed to characterize the altered keratinization and maturation patterns in this disease before and during complete clinical remission on therapy with etretinate. Anticytokeratin antibody KL1 showed no significant difference in reaction pattern either between healthy controls and PPK or following therapy. Earlier expression of both filaggrin and involucrin was found in PPK in comparison with the controls. During etretinate therapy the filaggrin pattern returned to normal, whereas the altered involucrin pattern was not influenced. Ultrastructural investigations before treatment revealed tightly packed tonofibrils (TF) and large masses of keratohyalin (KH) granules with abnormal configuration. During therapy the TF and KH granules were reduced in number and size. KH granules now showed frayed borders. Moreover, a transitional cell zone, focal parakeratosis with lipid droplets, and dyskeratotic cells became apparent. The normalization of filaggrin pattern accompanying the clinical remission of these lesions implies a role of this keratinocyte differentiation protein in the pathogenesis of these lesions. Since etretinate is assumed to act at a very late stage of epidermal differentiation, there was no influence on the altered expression of involucrin during etretinate therapy. Despite the clinical remission, fine structural abnormalities persisted, indicating that the deviations from the normal keratinocyte differentiation program in PKK occur very early.
Fartasch
M
M
Department of Dermatology, University of Erlangen-Nürnberg, West Germany.
Vigneswaran
N
N
Diepgen
T L
TL
Hornstein
O P
OP
D000328:Adult; D002454:Cell Differentiation / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D003594:Cytoplasmic Granules / Q000648:ultrastructure; D004817:Epidermis / Q000187:drug effects / Q000473:pathology; D005050:Etretinate / Q000627:therapeutic use*; D000091344:Filaggrin Proteins; D006801:Humans; D007124:Immunoenzyme Techniques; D007381:Intermediate Filament Proteins / Q000032:analysis; D015603:Keratinocytes / Q000032:analysis / Q000187:drug effects / Q000473:pathology*; D007633:Keratins / Q000032:analysis; D007645:Keratoderma, Palmoplantar / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008854:Microscopy, Electron; D011498:Protein Precursors / Q000032:analysis; D013194:Staining and Labeling
C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D007381:Intermediate Filament Proteins; D011498:Protein Precursors; C032253:involucrin; D005050:Etretinate; D007633:Keratins